Technical Analysis for ROSGQ - Rosetta Genomics Ltd

Grade Last Price % Change Price Change
B 0.001 233.33% 0.0007
ROSGQ closed up 233.33 percent on Monday, May 16, 2022, on 7.73 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 233.33%
Narrow Range Bar Range Contraction 233.33%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rosetta Genomics Ltd Description

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Cancer Nose Prostate Cancer Oncology Kidney Diagnostic Tests Small Cell Genomics Urine Lung Cancer Pathology Tumor Aspi Carcinoma Infectious Causes Of Cancer Fluorescence Genetics Melanoma Non Small Cell Lung Cancer Thyroid Bladder Cancer Small Cell Lung Cancer Diagnostic Solutions Metastatic Cancer Hybridization Mutation Fluorescence In Situ Hybridization Hematuria In Situ Hybridization Microrna Rehovot

Is ROSGQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.39
52 Week Low 0.0001
Average Volume 9,002
200-Day Moving Average 0.0473
50-Day Moving Average 0.0005
20-Day Moving Average 0.0003
10-Day Moving Average 0.0002
Average True Range 0.0007
RSI 51.92
ADX 29.86
+DI 55.0000
-DI 25.0000
Chandelier Exit (Long, 3 ATRs) -0.0010
Chandelier Exit (Short, 3 ATRs) 0.0022
Upper Bollinger Bands 0.0010
Lower Bollinger Band -0.0004
Percent B (%b) 1.0
BandWidth 466.6667
MACD Line -0.0002
MACD Signal Line -0.0004
MACD Histogram 0.0002
Fundamentals Value
Market Cap 5.93 Thousand
Num Shares 5.93 Million
EPS -6.41
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 0.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0010
Resistance 3 (R3) 0.0010 0.0010 0.0010
Resistance 2 (R2) 0.0010 0.0010 0.0010 0.0010
Resistance 1 (R1) 0.0010 0.0010 0.0010 0.0010 0.0010
Pivot Point 0.0010 0.0010 0.0010 0.0010 0.0010
Support 1 (S1) 0.0010 0.0010 0.0010 0.0010 0.0010
Support 2 (S2) 0.0010 0.0010 0.0010 0.0010
Support 3 (S3) 0.0010 0.0010 0.0010
Support 4 (S4) 0.0010